Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare muscle disorders. They generate revenue primarily through the development and commercialization of their proprietary drug candidates. Founded in 2017, the company has made significant strides in advancing its lead product, EDG-5506, which is designed to address Duchenne muscular dystrophy and Becker muscular dystrophy. Edgewise Therapeutics leverages its expertise in muscle biology and small molecule therapeutics to create impactful solutions for patients with serious muscle diseases.

Recent Posts by Edgewise Therapeutics

1-20 of 24